A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of TAK-058 and Ondansetron on P50 Auditory Gating in Subjects With Stable Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs Ondansetron (Primary) ; TAK 058 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- Sponsors Takeda
- 07 Jun 2017 Biomarkers information updated
- 24 Oct 2016 Status changed from completed to discontinued.
- 09 Jun 2016 Status changed from recruiting to completed.